HomeCompareVACC vs ADC

VACC vs ADC: Dividend Comparison 2026

VACC yields 40.00% · ADC yields 4.11%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VACC wins by $54.9K in total portfolio value
10 years
VACC
VACC
● Live price
40.00%
Share price
$5.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$231.9K
Annual income
$39,181.04
Full VACC calculator →
ADC
Agree Realty Corporation
● Live price
4.11%
Share price
$75.38
Annual div
$3.10
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$176.9K
Annual income
$79,647.25
Full ADC calculator →

Portfolio growth — VACC vs ADC

📍 VACC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVACCADC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VACC + ADC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VACC pays
ADC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VACC
Annual income on $10K today (after 15% tax)
$3,400.00/yr
After 10yr DRIP, annual income (after tax)
$33,303.88/yr
ADC
Annual income on $10K today (after 15% tax)
$349.45/yr
After 10yr DRIP, annual income (after tax)
$67,700.16/yr
At 15% tax rate, ADC beats the other by $34,396.28/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VACC + ADC for your $10,000?

VACC: 50%ADC: 50%
100% ADC50/50100% VACC
Portfolio after 10yr
$204.4K
Annual income
$59,414.14/yr
Blended yield
29.07%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ADC right now

VACC
Analyst Ratings
3
Buy
1
Hold
Consensus: Buy
Altman Z
0.8
Piotroski
2/9
ADC
Analyst Ratings
1
Strong
22
Buy
9
Hold
Consensus: Buy
Price Target
$81.06
+7.5% upside vs current
Range: $75.00 — $84.50
Altman Z
1.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VACC buys
0
ADC buys
0
No recent congressional trades found for VACC or ADC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVACCADC
Forward yield40.00%4.11%
Annual dividend / share$2.00$3.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.4%
Portfolio after 10y$231.9K$176.9K
Annual income after 10y$39,181.04$79,647.25
Total dividends collected$174.4K$154.7K
Payment frequencyquarterlymonthly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: VACC vs ADC ($10,000, DRIP)

YearVACC PortfolioVACC Income/yrADC PortfolioADC Income/yrGap
1← crossover$14,700$4,000.00$10,987$577.21+$3.7KVACC
2$21,224$5,495.33$12,293$855.34+$8.9KVACC
3$30,125$7,415.26$14,088$1,290.70+$16.0KVACC
4$42,071$9,836.48$16,660$1,994.91+$25.4KVACC
5$57,854$12,838.17$20,525$3,181.85+$37.3KVACC
6$78,403$16,499.54$26,654$5,286.90+$51.7KVACC
7$104,788$20,897.28$37,006$9,259.47+$67.8KVACC
8$138,226$26,102.79$55,862$17,338.74+$82.4KVACC
9$180,082$32,179.61$93,452$35,300.32+$86.6KVACC
10$231,869$39,181.04$176,931$79,647.25+$54.9KVACC

VACC vs ADC: Complete Analysis 2026

VACCStock

Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.

Full VACC Calculator →

ADCREIT

Agree Realty Corporation is a publicly traded real estate investment trust primarily engaged in the acquisition and development of properties net leased to industry-leading retail tenants. As of September 30, 2020, the Company owned and operated a portfolio of 1,027 properties, located in 45 states and containing approximately 21.0 million square feet of gross leasable area. The Company's common stock is listed on the New York Stock Exchange under the symbol ADC.

Full ADC Calculator →
📬

Get this VACC vs ADC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VACC vs SCHDVACC vs JEPIVACC vs OVACC vs KOVACC vs MAINVACC vs NNNVACC vs EPRTVACC vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.